Biomarkers may be the key to unlocking the full potential of ADCs.
26 Aug 2026
bởiPank Jit Sin
Antibody-drug conjugates (ADCs) are an important therapeutic option in advanced non-small cell lung cancer (NSCLC), but the right patient selection remains a major challenge. Professor David P. Carbone, Director, Thoracic Oncology Center, Ohio State University Medical Center, Ohio, US, discussed the evolving role of biomarkers in guiding therapy with ADC.
